Specific Protein Content of Pools of Plasma for Fractionation from Different Sources: Impact of Frequency of Donations

Overview

Journal Vox Sang

Specialty Hematology

Date 2010 Sep 16

PMID 20840337

Citations 16

Authors

R Laub

S Baurin

D Timmerman

T Branckaert

P Strengers

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Plasma pools for the production of human plasma medicinal products are distinguished according to the collection method (recovered or apheresis plasma) and the donor remuneration status. National regulations and the physical status of the donor determine the donation frequency and plasma volume per session. Relevant protein contents of different types of pools have not fully been compared.

Materials And Methods: We compared the levels of total protein, 15 main relevant plasma protein markers, and anti-B19 and anti-Streptococcus pneumoniae IgG in single-type pools of donations from different countries (Belgium, Finland, France, the Netherlands, Germany, United States). Both recovered plasma from non-remunerated donors and apheresis plasma from remunerated and non-remunerated donors were studied.

Results: Pools from paid US high-frequency, high-volume plasmapheresis donors showed significantly lower total protein (-9%), albumin (-15%), total IgG (-24%), IgM (-28%), hemopexin (-11%) and retinol-binding protein (-10%) but higher C1-inhibitor, pre-albumin and C-reactive protein contents than pools from unpaid European Union (EU) or US whole-blood or plasmapheresis donors. In contrast to pools from compensated EU plasmapheresis donors, pools from unpaid whole-blood or plasmapheresis donors showed no significant differences, whatever the collection method or country. Reductions in specific protein contents correlated well with protein half-life.

Conclusion: These results should be taken into account with regard to donor health management and protein recovery.

Citing Articles

Securing commitment and control for the supply of plasma derivatives for public health systems. I: A short review of the global landscape.

von Bonsdorff L, Farrugia A, Candura F, OLeary P, Vesga M, De Angelis V Vox Sang. 2024; 120(2):114-123.

PMID: 39477346 PMC: 11839246. DOI: 10.1111/vox.13758.

Securing commitment and control for the supply of plasma derivatives for public health systems. II: A survey of national pathways.

von Bonsdorff L, Farrugia A, Candura F, OLeary P, Vesga M, De Angelis V Vox Sang. 2024; 120(2):124-131.

PMID: 39477331 PMC: 11839248. DOI: 10.1111/vox.13759.

The effect of donation frequency on donor health in blood donors donating plasma by plasmapheresis: study protocol for a randomized controlled trial.

Haugen M, Magnussen K, Aarsland T, Nissen-Meyer L, Strand T Trials. 2024; 25(1):175.

PMID: 38468338 PMC: 10926559. DOI: 10.1186/s13063-024-08035-7.

Oedema: a rare complication of plasma donation in an adolescent female.

Shychuk E, Glasford K, Shychuk A, Joseph N BMJ Case Rep. 2023; 16(3).

PMID: 36948523 PMC: 10040018. DOI: 10.1136/bcr-2023-254908.

Analysis of influencing factors of serum total protein and serum calcium content in plasma donors.

Liu B, Dong D, Wang Z, Gao Y, Yu D, Ye S PeerJ. 2022; 10:e14474.

PMID: 36523465 PMC: 9745925. DOI: 10.7717/peerj.14474.

References

Caspari G, Gerlich W, Gurtler L . Paying for blood donations--still a risk?. Vox Sang. 2003; 85(1):52. DOI: 10.1046/j.1423-0410.2003.00321.x. View

Easton J, Hardwicke J, Whitehead P . The estimation of two alpha(1) glycoproteins (orosomucoid and another alpha(1) acid glycoprotein) in health and disease. J Clin Pathol. 1962; 15(6):585-90. PMC: 480464. DOI: 10.1136/jcp.15.6.585. View

Marshall W . Nutritional assessment: its role in the provision of nutritional support. J Clin Pathol. 2008; 61(10):1083-8. DOI: 10.1136/jcp.2007.051813. View

Jefferson T, Ferroni E, Curtale F, Rossi P, Borgia P . Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old. Lancet Infect Dis. 2006; 6(7):405-10. DOI: 10.1016/S1473-3099(06)70520-5. View

Concepcion N, Frasch C . Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2001; 8(2):266-72. PMC: 96047. DOI: 10.1128/CDLI.8.2.266-272.2001. View

Schulzki T, Seidel K, Storch H, Karges H, Kiessig S, Schneider S . A prospective multicentre study on the safety of long-term intensive plasmapheresis in donors (SIPLA). Vox Sang. 2006; 91(2):162-73. DOI: 10.1111/j.1423-0410.2006.00794.x. View

Hellstern P, Bach J, Haubelt H, Hitzler W, Mathis S, Vogt A . The impact of the intensity of serial automated plasmapheresis and the speed of deep-freezing on the quality of plasma. Transfusion. 2002; 41(12):1601-5. DOI: 10.1046/j.1537-2995.2001.41121601.x. View

Runkel S, Haubelt H, Hitzler W, Hellstern P . The quality of plasma collected by automated apheresis and of recovered plasma from leukodepleted whole blood. Transfusion. 2005; 45(3):427-32. DOI: 10.1111/j.1537-2995.2005.04276.x. View

SALVAGGIO J, Arquembourg P, Bickers J, Bice D . The effect of prolonged plasmapheresis on immunoglobulins, other serum proteins, delayed hypersensitivity and phytohemagglutinin-induced lymphocyte transformation. Int Arch Allergy Appl Immunol. 1971; 41(6):883-94. DOI: 10.1159/000230580. View

10.

Lamb M . Source plasma: future outlook. Transfusion. 2009; 49(7 Pt 2):1520-6. DOI: 10.1111/j.1537-2995.2009.02264.x. View

11.

Bechtloff S, Tran-My B, Haubelt H, Stelzer G, Anders C, Hellstern P . A prospective trial on the safety of long-term intensive plasmapheresis in donors. Vox Sang. 2005; 88(3):189-95. DOI: 10.1111/j.1423-0410.2005.00632.x. View

12.

van der Poel C, Seifried E, Schaasberg W . Paying for blood donations: still a risk?. Vox Sang. 2002; 83(4):285-93. DOI: 10.1046/j.1423-0410.2002.00239.x. View

13.

Modrof J, Berting A, Tille B, Klotz A, Forstner C, Rieger S . Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins. Transfusion. 2007; 48(1):178-86. DOI: 10.1111/j.1537-2995.2007.01503.x. View

14.

Kalibatas V . Payment for whole blood donations in Lithuania: the risk for infectious disease markers. Vox Sang. 2007; 94(3):209-215. DOI: 10.1111/j.1423-0410.2007.01015.x. View

15.

Thomas I, Di Giambattista M, Gerard C, Mathys E, Hougardy V, Latour B . Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non-structural viral proteins. Vox Sang. 2003; 84(4):300-7. DOI: 10.1046/j.1423-0410.2003.00299.x. View

16.

Quinlan G, Martin G, Evans T . Albumin: biochemical properties and therapeutic potential. Hepatology. 2005; 41(6):1211-9. DOI: 10.1002/hep.20720. View

17.

Delanghe J, Langlois M . Hemopexin: a review of biological aspects and the role in laboratory medicine. Clin Chim Acta. 2001; 312(1-2):13-23. DOI: 10.1016/s0009-8981(01)00586-1. View

18.

Cohen M, OBERMAN H . Safety and long-term effects of plasmapheresis. Transfusion. 1970; 10(2):58-66. DOI: 10.1111/j.1537-2995.1970.tb00706.x. View

19.

Beall B, McEllistrem M, Gertz Jr R, Wedel S, Boxrud D, Gonzalez A . Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol. 2006; 44(3):999-1017. PMC: 1393141. DOI: 10.1128/JCM.44.3.999-1017.2006. View

20.

Burnouf T . Modern plasma fractionation. Transfus Med Rev. 2007; 21(2):101-17. PMC: 7125842. DOI: 10.1016/j.tmrv.2006.11.001. View